Intravitreal Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: A One-year Prospective Study

Eyes with neovascular AMD treated with intravitreal bevacizumab over 12 months had significant anatomical and functional improvement. Further studies need to confirm the long-term efficacy of this treatment.